Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
6990
Clasificación en acciones
#1583
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company,... Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Precio por acción
$57.07
Capitalización bursátil
$13.64B
Cambio (1 día)
-5.37%
Cambio (1 año)
-2.19%
País
CN
Comercio Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)
Categoría
Healthcare
Ingresos de Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)
Ingresos en Oct 2026 TTM: 0
Según los últimos informes financieros de Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. desde 2021 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2025 | $294.14M | 11.07% |
| 2024 | $264.83M | 21.69% |
| 2023 | $217.63M | 86.73% |
| 2022 | $116.55M | 2,229.88% |
| 2021 | $5.00M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $10.11B | - |
BE
|
|
| $6.02B | - |
NL
|
